Last reviewed · How we verify

Xylocaine with Epinephrine

Vrije Universiteit Brussel · FDA-approved active Small molecule

Xylocaine (lidocaine) blocks sodium channels to produce local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic absorption.

Xylocaine (lidocaine) blocks sodium channels to produce local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic absorption. Used for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameXylocaine with Epinephrine
Also known asSubconjucntival injection with xylocain injection
SponsorVrije Universiteit Brussel
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels; alpha-1 adrenergic receptors
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that reversibly inhibits sodium influx through nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a sympathomimetic agent that causes vasoconstriction of local blood vessels, which slows the rate of lidocaine absorption into the systemic circulation, thereby extending the duration of anesthesia and reducing toxicity risk.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: